Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

The report suggests that USAID could have seen its 10,000-strong workforce reduced to just 300, with the new figure emerging ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organization ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...